https://seekingalpha.com/article/4761269-avidity-biosciences-stock-looks-tempting-but-wait-interim-phase-3-data [Seeking Alpha]
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Despite promising data from phase 1/2 trials, the stock has fallen 35% since its November peak, partly due to Fulcrum Therapeutics exiting the FSHD race. The market sizes for DM1, FSHD, and DMD are significant but competitive, with Sarepta dominating DMD. RNA's $4bn valuation seems fair; I might consider a small investment but will wait for interim phase 3 data. Richard Drury When I covered Avidity Biosciences, Inc. ( NASDAQ: RNA ) a few months ago in October, I said that while I liked the company, I thought it was too expensive. I said that the “ship had sailed.” A month after that, the stock reached its all-time high, but About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer the following:- Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring hands-on support, our in-house experts go th
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an "underperform" rating on the stock.MarketBeat
- Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common StockGlobeNewswire
FULC
Earnings
- 10/29/25 - Miss
FULC
Sec Filings
- 12/17/25 - Form 4
- 12/15/25 - Form 144
- 12/11/25 - Form 8-K
- FULC's page on the SEC website